DIR Return Create A Forum - Home
       ---------------------------------------------------------
       MS Speaks
  HTML https://msspeaks.createaforum.com
       ---------------------------------------------------------
       *****************************************************
   DIR Return to: TYSABRI (natalizumab)
       *****************************************************
       #Post#: 1924--------------------------------------------------
       (Abst.) Refractory epilepsy following natalizumab-associated PML
       By: agate Date: December 19, 2017, 6:43 pm
       ---------------------------------------------------------
       From PubMed, December 19, 2017:
       [quote]Mult Scler Relat Disord. 2017 Dec 13;20:1-2.
       Refractory epilepsy following natalizumab associated PML
       Abkur TM1, Kearney H2, Hennessy MJ2.
       Author information
       1
       Department of Neurology, Galway University Hospital, Galway,
       Ireland. Electronic address: tarig1982@hotmail.com.
       2
       Department of Neurology, Galway University Hospital, Galway,
       Ireland.
       Natalizumab treatment of multiple sclerosis (MS) is associated
       with a risk of developing progressive multifocal
       leukoencephalopathy (PML), a rare opportunistic viral
       demyelinating disease caused by reactivation of John Cunningham
       virus (JCV). Herein we report a case of a 40-year-old woman who
       developed refractory temporal lobe epilepsy one year after
       recovery from Natalizumab-induced PML. Localisation related
       epilepsy, which may be refractory in nature, as in this case
       report, is a potential chronic disabling complication of PML.
       Epilepsy in this context likely reflects grey matter
       involvement, which may then act as cortical epileptogenic
       zone.[/quote]
  HTML https://www.ncbi.nlm.nih.gov/pubmed/29253743
       *****************************************************